Targeted Antibiotics Market By Action Mechanism (Protein, DNA, RNA, Cell Wall Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporins, Fluoroquinolones); By Region (U.S., Canada, Mexico, Rest of North America, UK, France, Germany, Italy, Spain, Benelux Union, Nordic Countries , Rest of Europe, China, Japan, India, South Korea, Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia, Brazil, Argentina Rest of Latin America, GCC countries, Southern Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Global targeted antibiotics market was valued at US$ 19915.11 in 2018 and is expected to reach US$ 21031.51 million by 2027, growing at an estimated rate of 4.4% over the next eight years. Antibiotic is an antimicrobial agent that battles bacterial infections, and sometimes protozoan infections. These are also used to treat many diseases such as strep throat, infections of the urinary tract, infections of the sinus, pneumonia, infections of the skin, infections of the ears and others. There are many ways to classify antibiotics but the most general classification is based on their activity range, chemical structures and mode of action. The market for antibiotic-class beta-lactam and beta-lactamase inhibitors is currently high among healthcare providers. Since the days of leeches and humors, antibiotics have become more and more individualized, but in the last 15 years, an influx of patient data in the form of genetic information and electronic health records (EHRs) has sharpened the physician's view of the individual patient - and of therapies tailored to their specific needs. Such targeted care is referred to as targeted antibiotics - tailoring treatment to a specific patient i.e. designing a medical treatment based on diagnosis, clinical condition, history of patients, physiology of the body and other patient and disease-related factors. Often called precision medicine, stratified medicine or P4 medicine is targeted antibiotics. Diagnostic screening is often done in targeted antibiotics to determine appropriate and effective therapies based on the genetic content of the patient, or other molecular or cellular analysis. Targeted antibiotics have the best response and highest safety margin to ensure enhanced patient care by allowing every patient to attain earlier diagnosis, risk assessment, and best treatment. Additionally, targeted antibiotics market offer opportunities to improve health care by lowering overall treatment costs.
Supporting government policy, such as the GAIN Act (Generating Antibiotics Incentives Now), is expected to speed up the approval process. GAIN Act includes provisions that promote the production of antibiotic-resistant pathogens therapies. Diarrhoea appears to be the leading cause of death in children worldwide and needs antibiotic intervention to avoid morbidity. HIV / AIDS, influenza, malaria, and tuberculosis are other infectious diseases known to pose a high burden. Moreover, the emergence of new pathogens, such as the Zika and Ebola virus, also promote antibiotic production and uptake.
The increase in the prevalence of different types of cancer, the availability of personalized medicine therapy in cancer drugs and numerous other signs of disease, lesser side effects of personalized medicine therapy, high penetration in developed markets and the development of novel medicines are factors driving the global market for personalized medicines. Prostate cancer is leading cancer in men and is considered to be the second leading cause of death due to cancer. Prevalence of the same disease type is high among the elderly population. Because this cancer causes little discomfort and takes several years to grow, doctors and patients face the challenge of finding appropriate treatment methods for localized prostate cancer, biochemically recurrent prostate cancer, and later-stage cancer. Age-related changes can affect all of these therapies, including metastatic disease, and alter the risk-benefit ratio of these treatments. New tools are being created to better predict who will respond to the therapy, such as the Comprehensive Geriatric Assessment. These methods may also assist in predicting a specific prostate cancer on patient's remaining life expectancy. Such factors have led the growth of targeted antibiotics market
Nevertheless, high competition among existing market players, strict government regulations relating to product approval, and lack of awareness among rural people in developing economies are likely to hamper the market in the coming years. Although personalized medicine can be implemented in rural and underserved areas if it is combined with telemedicine systems, the right resources, staffing, and coordination are not cost-effective in nature. Such factors are expected to hinder the global targeted antibiotics market over the forecast period.
Early and appropriate antibiotic treatment of patients suspected of having sepsis is associated with reduced mortality. The increasing prevalence of antimicrobial resistance reduces the efficacy of targeted antibiotic therapy guidelines derived from population data. This problem is particularly severe for patients in developing countries. This has been hypothesized by applying machine learning approaches to readily collect patient data like clinical, demographic and living conditions. It would be possible to obtain personalized predictions for targeted antibiotic choices. Applying machine learning algorithms to patient data that are readily available even in resource-limited hospitals can provide highly informative predictions on antibiotic susceptibilities to guide appropriate targeted antibiotic therapy. These strategies, when used as a decision support tool, have the potential to improve treatment selection, patient outcomes and reduce the antimicrobial resistance burden. Also, the emergence of microbes resistant to common antibiotics represents a current threat to human health. It has been recently acknowledged that non-antibiotic labeled drugs may promote antibiotic-resistance mechanisms in the human microbiome by presenting a secondary antibiotic activity. Hence, the development of machine learning procedures to identify antibiotic activity in human-targeted compounds may assist in preventing the emergence of resistant microbes. Doctors use artificial intelligence (AI) to create precise therapies for complex diseases at organizations ranging from large corporations to university-led and government-funded research collectives. Their main goal is to gain insight into what keeps patients healthy at the individual level from increasingly large and open data sets. These insights may direct the development of new medicines, discover new uses for old ones, propose custom combinations, and predict the risk of disease. Such factors are expected to propel the market growth of targeted antibiotics market in the future years.
By Action Mechanism Insights
Based on action mechanism, the targeted antibiotics Market is segmented into Protein, DNA, RNA and Cell Wall Synthesis Inhibitors. Modern advancements and innovations in personalized medicine rely on technology that confirms the basic biology, RNA, DNA, or protein of a patient, which ultimately leads to disease confirmation. Another process, called RNA-seq, can demonstrate which RNA molecules are involved in specific diseases. Unlike DNA, RNA levels can change with environmental response. RNA sequencing can, therefore, provide a broader understanding of a person's health condition. Pathwork Tissue of Origin Test Kit - FFPE tests the degree of similarity between the patterns of RNA expression in a patient's tumor and the patterns of RNA expression in a database of fifteen forms of tumors (poorly differentiated, undifferentiated, and metastatic) that were identified according to the then existing clinical and pathological practice. Brentuximab Vedotin (AdcetrisTM) targets CD30 protein present on the surface of some cells to treat Hodgkin's lymphoma and systemic large cell anaplastic lymphoma.
By Drug Class Insights
Based on drug class, the targeted antibiotics market is segmented into Penicillin, Cephalosporins, and Fluoroquinolones. Cephalosporins are indicated for the preventive health care and treatment of infections caused by bacteria easily affected by this particular form of antibiotic. Cephalosporins of the first generation are primarily active against Gram-positive bacteria, such as Staphylococcus and Streptococcus. Thus they are mostly used for infections of the skin and soft tissue. Cephalosporins successive generations have an increased activity mechanism against Gram-negative bacteria although often with decreased activity of the same. The antibiotic may be used in patients allergic to penicillin because of the different antibiotic structures of the β-lactam. The drug can be excreted inside the urine.
By Regional Insights
In terms of sales, North America targeted antibiotics market dominates accounted the largest share, led by Europe. The market is expanding in Asia Pacific and Latin America. The pattern is projected to also continue over the forecast period. The availability of a large pool of patients, the growth of the healthcare industry and increased government spending in healthcare reforms are expected to drive the targeted antibiotics market.
Targeted Antibiotics Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of targeted antibiotics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Major players operating in the global targeted antibiotics market are Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline plc., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V., Eli Lilly and Company, Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Biogen, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, and Sanofi Genzyme.
Targeted Antibiotics Market:
- By Action Mechanism
- Protein
- DNA
- RNA
- Cell Wall Synthesis Inhibitors
- By Drug Class
- Penicillin
- Cephalosporins
- Fluoroquinolones
- By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Targeted Antibiotics Market
6. Market
Synopsis: Targeted Antibiotics Market
7. Targeted
Antibiotics Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Targeted Antibiotics Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Targeted Antibiotics Market
7.6. Porter’s
Five Force Analysis
8. Global
Targeted Antibiotics Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Targeted Antibiotics Market Revenue (US$
Mn)
8.2. Global
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
8.2.1. Protein
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. DNA
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. RNA
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Cell
Wall Synthesis Inhibitors
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 – 2018
8.2.4.3. Market
Forecast, 2019 – 2027
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Action Mechanism
9. Global
Targeted Antibiotics Market Analysis and
Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
9.2.1. Penicillin
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Cephalosporins
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Fluoroquinolones
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By Drug
Class
10. North
America Targeted Antibiotics Market
Analysis and Forecasts, 2019 - 2027
10.1. Overview
10.1.1. North
America Targeted Antibiotics Market
Revenue (US$ Mn)
10.2. North
America Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
10.2.1. Protein
10.2.2. DNA
10.2.3. RNA
10.2.4. Cell
Wall Synthesis Inhibitors
10.3. North
America Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
10.3.1. Penicillin
10.3.2. Cephalosporins
10.3.3. Fluoroquinolones
10.4. North
America Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
10.4.1.1.1. Protein
10.4.1.1.2. DNA
10.4.1.1.3. RNA
10.4.1.1.4. Cell
Wall Synthesis Inhibitors
10.4.1.2. U.S
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
10.4.1.2.1. Penicillin
10.4.1.2.2. Cephalosporins
10.4.1.2.3. Fluoroquinolones
10.4.2. Canada
10.4.2.1. Canada
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
10.4.2.1.1. Protein
10.4.2.1.2. DNA
10.4.2.1.3. RNA
10.4.2.1.4. Cell
Wall Synthesis Inhibitors
10.4.2.2. Canada
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
10.4.2.2.1. Penicillin
10.4.2.2.2. Cephalosporins
10.4.2.2.3. Fluoroquinolones
10.4.3. Mexico
10.4.3.1. Mexico
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
10.4.3.1.1. Protein
10.4.3.1.2. DNA
10.4.3.1.3. RNA
10.4.3.1.4. Cell
Wall Synthesis Inhibitors
10.4.3.2. Mexico
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
10.4.3.2.1. Penicillin
10.4.3.2.2. Cephalosporins
10.4.3.2.3. Fluoroquinolones
10.4.4. Rest of
North America
10.4.4.1. Rest
of North America Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Action Mechanism
10.4.4.1.1. Protein
10.4.4.1.2. DNA
10.4.4.1.3. RNA
10.4.4.1.4. Cell
Wall Synthesis Inhibitors
10.4.4.2. Rest
of North America Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
10.4.4.2.1. Penicillin
10.4.4.2.2. Cephalosporins
10.4.4.2.3. Fluoroquinolones
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By
Action Mechanism
10.5.3. By Drug
Class
11. Europe
Targeted Antibiotics Market Analysis and
Forecasts, 2019 - 2027
11.1. Overview
11.1.1. Europe
Targeted Antibiotics Market Revenue (US$
Mn)
11.2. Europe
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
11.2.1. Protein
11.2.2. DNA
11.2.3. RNA
11.2.4. Cell
Wall Synthesis Inhibitors
11.3. Europe
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
11.3.1. Penicillin
11.3.2. Cephalosporins
11.3.3. Fluoroquinolones
11.4. Europe
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1. France
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
11.4.1.1.1. Protein
11.4.1.1.2. DNA
11.4.1.1.3. RNA
11.4.1.1.4. Cell
Wall Synthesis Inhibitors
11.4.1.2. France
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
11.4.1.2.1. Penicillin
11.4.1.2.2. Cephalosporins
11.4.1.2.3. Fluoroquinolones
11.4.2. The UK
11.4.2.1. The
UK Targeted Antibiotics Market Revenue
(US$ Mn) and Forecasts, By Action Mechanism
11.4.2.1.1. Protein
11.4.2.1.2. DNA
11.4.2.1.3. RNA
11.4.2.1.4. Cell
Wall Synthesis Inhibitors
11.4.2.2. The
UK Targeted Antibiotics Market Revenue
(US$ Mn) and Forecasts, By Drug Class
11.4.2.2.1. Penicillin
11.4.2.2.2. Cephalosporins
11.4.2.2.3. Fluoroquinolones
11.4.3. Spain
11.4.3.1. Spain
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
11.4.3.1.1. Protein
11.4.3.1.2. DNA
11.4.3.1.3. RNA
11.4.3.1.4. Cell
Wall Synthesis Inhibitors
11.4.3.2. Spain
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
11.4.3.2.1. Penicillin
11.4.3.2.2. Cephalosporins
11.4.3.2.3. Fluoroquinolones
11.4.4. Germany
11.4.4.1. Germany
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
11.4.4.1.1. Protein
11.4.4.1.2. DNA
11.4.4.1.3. RNA
11.4.4.1.4. Cell
Wall Synthesis Inhibitors
11.4.4.2. Germany
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
11.4.4.2.1. Penicillin
11.4.4.2.2. Cephalosporins
11.4.4.2.3. Fluoroquinolones
11.4.5. Italy
11.4.5.1. Italy
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
11.4.5.1.1. Protein
11.4.5.1.2. DNA
11.4.5.1.3. RNA
11.4.5.1.4. Cell
Wall Synthesis Inhibitors
11.4.5.2. Italy
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
11.4.5.2.1. Penicillin
11.4.5.2.2. Cephalosporins
11.4.5.2.3. Fluoroquinolones
11.4.6. Nordic
Countries
11.4.6.1. Nordic
Countries Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
11.4.6.1.1. Protein
11.4.6.1.2. DNA
11.4.6.1.3. RNA
11.4.6.1.4. Cell
Wall Synthesis Inhibitors
11.4.6.2. Nordic
Countries Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
11.4.6.2.1. Penicillin
11.4.6.2.2. Cephalosporins
11.4.6.2.3. Fluoroquinolones
11.4.6.3. Nordic
Countries Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux
Union Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
11.4.7.1.1. Protein
11.4.7.1.2. DNA
11.4.7.1.3. RNA
11.4.7.1.4. Cell
Wall Synthesis Inhibitors
11.4.7.2. Benelux
Union Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
11.4.7.2.1. Penicillin
11.4.7.2.2. Cephalosporins
11.4.7.2.3. Fluoroquinolones
11.4.7.3. Benelux
Union Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The
Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest
of Europe Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
11.4.8.1.1. Protein
11.4.8.1.2. DNA
11.4.8.1.3. RNA
11.4.8.1.4. Cell
Wall Synthesis Inhibitors
11.4.8.2. Rest
of Europe Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
11.4.8.2.1. Penicillin
11.4.8.2.2. Cephalosporins
11.4.8.2.3. Fluoroquinolones
11.5. Key
Segment for Channeling Investments
11.5.1. By
Country
11.5.2. By
Action Mechanism
11.5.3. By Drug
Class
12. Asia
Pacific Targeted Antibiotics Market
Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Asia
Pacific Targeted Antibiotics Market
Revenue (US$ Mn)
12.2. Asia
Pacific Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
12.2.1. Protein
12.2.2. DNA
12.2.3. RNA
12.2.4. Cell
Wall Synthesis Inhibitors
12.3. Asia
Pacific Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
12.3.1. Penicillin
12.3.2. Cephalosporins
12.3.3. Fluoroquinolones
12.4. Asia Pacific
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Country
12.4.1. China
12.4.1.1. China
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
12.4.1.1.1. Protein
12.4.1.1.2. DNA
12.4.1.1.3. RNA
12.4.1.1.4. Cell
Wall Synthesis Inhibitors
12.4.1.2. China
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
12.4.1.2.1. Penicillin
12.4.1.2.2. Cephalosporins
12.4.1.2.3. Fluoroquinolones
12.4.2. Japan
12.4.2.1. Japan
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
12.4.2.1.1. Protein
12.4.2.1.2. DNA
12.4.2.1.3. RNA
12.4.2.1.4. Cell
Wall Synthesis Inhibitors
12.4.2.2. Japan
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
12.4.2.2.1. Penicillin
12.4.2.2.2. Cephalosporins
12.4.2.2.3. Fluoroquinolones
12.4.3. India
12.4.3.1. India
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
12.4.3.1.1. Protein
12.4.3.1.2. DNA
12.4.3.1.3. RNA
12.4.3.1.4. Cell
Wall Synthesis Inhibitors
12.4.3.2. India
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
12.4.3.2.1. Penicillin
12.4.3.2.2. Cephalosporins
12.4.3.2.3. Fluoroquinolones
12.4.4. New
Zealand
12.4.4.1. New
Zealand Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
12.4.4.1.1. Protein
12.4.4.1.2. DNA
12.4.4.1.3. RNA
12.4.4.1.4. Cell
Wall Synthesis Inhibitors
12.4.4.2. New
Zealand Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
12.4.4.2.1. Penicillin
12.4.4.2.2. Cephalosporins
12.4.4.2.3. Fluoroquinolones
12.4.5. Australia
12.4.5.1. Australia
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
12.4.5.1.1. Protein
12.4.5.1.2. DNA
12.4.5.1.3. RNA
12.4.5.1.4. Cell
Wall Synthesis Inhibitors
12.4.5.2. Australia
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
12.4.5.2.1. Penicillin
12.4.5.2.2. Cephalosporins
12.4.5.2.3. Fluoroquinolones
12.4.6. South
Korea
12.4.6.1. South
Korea Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
12.4.6.1.1. Protein
12.4.6.1.2. DNA
12.4.6.1.3. RNA
12.4.6.1.4. Cell
Wall Synthesis Inhibitors
12.4.6.2. South
Korea Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
12.4.6.2.1. Penicillin
12.4.6.2.2. Cephalosporins
12.4.6.2.3. Fluoroquinolones
12.4.7. Southeast
Asia
12.4.7.1. Southeast
Asia Targeted Antibiotics Market Revenue
(US$ Mn) and Forecasts, By Action Mechanism
12.4.7.1.1. Protein
12.4.7.1.2. DNA
12.4.7.1.3. RNA
12.4.7.1.4. Cell
Wall Synthesis Inhibitors
12.4.7.2. Southeast
Asia Targeted Antibiotics Market Revenue
(US$ Mn) and Forecasts, By Drug Class
12.4.7.2.1. Penicillin
12.4.7.2.2. Cephalosporins
12.4.7.2.3. Fluoroquinolones
12.4.7.3. Southeast
Asia Targeted Antibiotics Market Revenue
(US$ Mn) and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest
of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest
of Asia Pacific Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Action Mechanism
12.4.8.1.1. Protein
12.4.8.1.2. DNA
12.4.8.1.3. RNA
12.4.8.1.4. Cell
Wall Synthesis Inhibitors
12.4.8.2. Rest
of Asia Pacific Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.4.8.2.1. Penicillin
12.4.8.2.2. Cephalosporins
12.4.8.2.3. Fluoroquinolones
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By
Action Mechanism
12.5.3. By Drug
Class
13. Middle
East and Africa Targeted Antibiotics
Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Middle
East and Africa Targeted Antibiotics
Market Revenue (US$ Mn)
13.2. Middle
East and Africa Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Action Mechanism
13.2.1. Protein
13.2.2. DNA
13.2.3. RNA
13.2.4. Cell
Wall Synthesis Inhibitors
13.3. Middle
East and Africa Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.3.1. Penicillin
13.3.2. Cephalosporins
13.3.3. Fluoroquinolones
13.4. Middle
East and Africa Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi
Arabia Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
13.4.1.1.1. Protein
13.4.1.1.2. DNA
13.4.1.1.3. RNA
13.4.1.1.4. Cell
Wall Synthesis Inhibitors
13.4.1.2. Saudi
Arabia Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
13.4.1.2.1. Penicillin
13.4.1.2.2. Cephalosporins
13.4.1.2.3. Fluoroquinolones
13.4.2. UAE
13.4.2.1. UAE
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
13.4.2.1.1. Protein
13.4.2.1.2. DNA
13.4.2.1.3. RNA
13.4.2.1.4. Cell
Wall Synthesis Inhibitors
13.4.2.2. UAE
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.4.2.2.1. Penicillin
13.4.2.2.2. Cephalosporins
13.4.2.2.3. Fluoroquinolones
13.4.3. Egypt
13.4.3.1. Egypt
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
13.4.3.1.1. Protein
13.4.3.1.2. DNA
13.4.3.1.3. RNA
13.4.3.1.4. Cell
Wall Synthesis Inhibitors
13.4.3.2. Egypt
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.4.3.2.1. Penicillin
13.4.3.2.2. Cephalosporins
13.4.3.2.3. Fluoroquinolones
13.4.4. Kuwait
13.4.4.1. Kuwait
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
13.4.4.1.1. Protein
13.4.4.1.2. DNA
13.4.4.1.3. RNA
13.4.4.1.4. Cell
Wall Synthesis Inhibitors
13.4.4.2. Kuwait
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.4.4.2.1. Penicillin
13.4.4.2.2. Cephalosporins
13.4.4.2.3. Fluoroquinolones
13.4.5. South
Africa
13.4.5.1. South
Africa Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
13.4.5.1.1. Protein
13.4.5.1.2. DNA
13.4.5.1.3. RNA
13.4.5.1.4. Cell
Wall Synthesis Inhibitors
13.4.5.2. South
Africa Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
13.4.5.2.1. Penicillin
13.4.5.2.2. Cephalosporins
13.4.5.2.3. Fluoroquinolones
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest
of Middle East & Africa Targeted Antibiotics Market Revenue (US$ Mn) and Forecasts, By
Action Mechanism
13.4.6.1.1. Protein
13.4.6.1.2. DNA
13.4.6.1.3. RNA
13.4.6.1.4. Cell
Wall Synthesis Inhibitors
13.4.6.2. Rest
of Middle East & Africa Targeted Antibiotics Market Revenue (US$ Mn) and Forecasts, By
Drug Class
13.4.6.2.1. Penicillin
13.4.6.2.2. Cephalosporins
13.4.6.2.3. Fluoroquinolones
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By
Action Mechanism
13.5.3. By Drug
Class
14. Latin
America Targeted Antibiotics Market
Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Latin
America Targeted Antibiotics Market
Revenue (US$ Mn)
14.2. Latin
America Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Action Mechanism
14.2.1. Protein
14.2.2. DNA
14.2.3. RNA
14.2.4. Cell
Wall Synthesis Inhibitors
14.3. Latin
America Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
14.3.1. Penicillin
14.3.2. Cephalosporins
14.3.3. Fluoroquinolones
14.4. Latin
America Targeted Antibiotics Market
Revenue (US$ Mn) and Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
14.4.1.1.1. Protein
14.4.1.1.2. DNA
14.4.1.1.3. RNA
14.4.1.1.4. Cell
Wall Synthesis Inhibitors
14.4.1.2. Brazil
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
14.4.1.2.1. Penicillin
14.4.1.2.2. Cephalosporins
14.4.1.2.3. Fluoroquinolones
14.4.2. Argentina
14.4.2.1. Argentina
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Action Mechanism
14.4.2.1.1. Protein
14.4.2.1.2. DNA
14.4.2.1.3. RNA
14.4.2.1.4. Cell
Wall Synthesis Inhibitors
14.4.2.2. Argentina
Targeted Antibiotics Market Revenue (US$
Mn) and Forecasts, By Drug Class
14.4.2.2.1. Penicillin
14.4.2.2.2. Cephalosporins
14.4.2.2.3. Fluoroquinolones
14.4.3. Rest of
Latin America
14.4.3.1. Rest
of Latin America Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Action Mechanism
14.4.3.1.1. Protein
14.4.3.1.2. DNA
14.4.3.1.3. RNA
14.4.3.1.4. Cell
Wall Synthesis Inhibitors
14.4.3.2. Rest
of Latin America Targeted Antibiotics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.4.3.2.1. Penicillin
14.4.3.2.2. Cephalosporins
14.4.3.2.3. Fluoroquinolones
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By
Action Mechanism
14.5.3. By Drug
Class
15. Competitive
Benchmarking
15.1. Market
Share Analysis, 2018
15.2. Global
Presence and Growth Strategies
15.2.1. Mergers
and Acquisitions
15.2.2. Product
Launches
15.2.3. Investments
Trends
15.2.4. R&D
Initiatives
16. Player
Profiles
16.1. Abbott
Laboratories
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key
Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business
Strategies
16.2. Amgen,
Inc
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key
Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business
Strategies
16.3. AstraZeneca
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT
Analysis
16.3.7. Business
Strategies
16.4. Bayer AG
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business
Strategies
16.5. Biogen
Inc
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business
Strategies
16.6. Bristol
Myers Squibb Co.
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business
Strategies
16.7. Daiichi
Sankyo Company, Ltd
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT
Analysis
16.7.7. Business
Strategies
16.8. Eli Lilly
and Company
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business
Strategies
16.9. F.
Hoffmann La Roche Ltd
16.9.1. Company
Details
16.9.2. Company
Overview
16.9.3. Product
Offerings
16.9.4. Key
Developments
16.9.5. Financial
Analysis
16.9.6. SWOT
Analysis
16.9.7. Business
Strategies
16.10. GlaxoSmithKline
plc
16.10.1. Company
Details
16.10.2. Company
Overview
16.10.3. Product
Offerings
16.10.4. Key
Developments
16.10.5. Financial
Analysis
16.10.6. SWOT
Analysis
16.10.7. Business
Strategies
16.11. Johnson
& Johnson Services, Inc
16.11.1. Company
Details
16.11.2. Company
Overview
16.11.3. Product
Offerings
16.11.4. Key
Developments
16.11.5. Financial
Analysis
16.11.6. SWOT
Analysis
16.11.7. Business
Strategies
16.12. Merck
& Co. Inc.
16.12.1. Company
Details
16.12.2. Company
Overview
16.12.3. Product
Offerings
16.12.4. Key
Developments
16.12.5. Financial
Analysis
16.12.6. SWOT
Analysis
16.12.7. Business
Strategies
16.13. Mylan
N.V
16.13.1. Company
Details
16.13.2. Company
Overview
16.13.3. Product
Offerings
16.13.4. Key
Developments
16.13.5. Financial
Analysis
16.13.6. SWOT
Analysis
16.13.7. Business
Strategies
16.14. Novartis
AG
16.14.1. Company
Details
16.14.2. Company
Overview
16.14.3. Product
Offerings
16.14.4. Key Developments
16.14.5. Financial
Analysis
16.14.6. SWOT
Analysis
16.14.7. Business
Strategies
16.15. Novo
Nordisk A/S
16.15.1. Company
Details
16.15.2. Company
Overview
16.15.3. Product
Offerings
16.15.4. Key
Developments
16.15.5. Financial
Analysis
16.15.6. SWOT
Analysis
16.15.7. Business
Strategies
16.16. Pfizer
Inc
16.16.1. Company
Details
16.16.2. Company
Overview
16.16.3. Product
Offerings
16.16.4. Key
Developments
16.16.5. Financial
Analysis
16.16.6. SWOT
Analysis
16.16.7. Business
Strategies
16.17. Sanofi
Genzyme
16.17.1. Company
Details
16.17.2. Company
Overview
16.17.3. Product
Offerings
16.17.4. Key
Developments
16.17.5. Financial
Analysis
16.17.6. SWOT
Analysis
16.17.7. Business
Strategies
16.18. Thermo
Fisher Scientific, Inc
16.18.1. Company
Details
16.18.2. Company
Overview
16.18.3. Product
Offerings
16.18.4. Key
Developments
16.18.5. Financial
Analysis
16.18.6. SWOT
Analysis
16.18.7. Business
Strategies
16.19. Other
Market Participants
Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
